Search Results
Jan 19, 2026, 08:38 ET Global Traffic Congestion Rankings Released: LEPAS L8 Redefines the Mobility Experience with Elegant Driving
capability. The LEPAS L8 is equipped with Chery Group's Super Hybrid System, featuring an industry-leading 44.5% thermal efficiency and fuel consumption as low as 4.2 L/100 km in charge-sustaining mode. Together, these technologies form the competitive advantage of the LEPAS L8 in congested driving scenarios—transforming
More news about: LEPAS
Jan 19, 2026, 08:35 ET 全球交通擁堵榜出爐，LEPAS L8以「優雅駕控」重塑出行體驗
路突發擁堵可能打亂行程規劃，頻繁啟停也可能影響出行體驗。LEPAS L8超過1300公里的綜合續航，無需頻繁規劃補能站點，打消里程焦慮；混動專用變速箱97.6%的傳動效率，讓低速行駛也絲滑平順，避免頓挫感對出行的影響。這份擁堵時依然從容的表現背後，是強大的技術支撐。LEPAS L8搭載奇瑞集團超級混動系統，以行業領先的44.5%熱效率和4.2L/100km的饋電油耗。這些技術共同構建了LEPAS L8在擁堵場景下的核心競爭力，讓每一次出行都成為從容愜意的優雅駕控體驗。在全球交通擁堵問題日益嚴峻的當下，LEPAS將智能駕駛輔助技術與新能源動力系統深度融合，不僅緩解了擁堵路況下的駕駛痛點，也重新定義了城市出行的優雅範式。隨著品牌在全球市場佈局的加速，將為全球更多用戶帶來優雅駕控的出行體驗，助力駕駛者在複雜都市交通中始終保持從容姿態。
More news about: LEPAS
Jan 19, 2026, 08:32 ET Global Traffic Congestion Rankings Released: LEPAS L8 Redefines the Mobility Experience with Elegant Driving
capability. The LEPAS L8 is equipped with Chery Group's Super Hybrid System, featuring an industry-leading 44.5% thermal efficiency and fuel consumption as low as 4.2 L/100 km in charge-sustaining mode. Together, these technologies form the competitive advantage of the LEPAS L8 in congested driving scenarios—transforming
More news about: LEPAS
Jan 19, 2026, 05:25 ET Shriram AMC Expands Fixed Income Suite with Launch of Shriram Money Market Fund
meeting the evolving liquidity, duration, and risk management needs of institutional treasuries, corporates, HNIs, and retirees.Mr. Kartik L Jain, MD & CEO, Shriram Asset Management Company Limited, said, "As liquidity management becomes a core component of portfolio construction
More news about: Shriram Asset Management Company Limited
Jan 19, 2026, 02:49 ET TCL conquista prêmios na CES 2026 por inovações nas categorias de TV, mobile e casa inteligente
Entre as inovações premiadas, a TV TCL X11L SQD-Mini LED recebeu amplo reconhecimento, incluindo o Gold Award de Tecnologia Inovadora de Display da International Data Group (IDG), em
More news about: TCL
Jan 19, 2026, 02:39 ET TCL conquista premios en la CES 2026 por innovaciones en las categorías de TV, mobile y hogar inteligente
Entre las innovaciones premiadas, el televisor TCL X11L SQD-Mini LED recibió un amplio reconocimiento, incluyendo el Gold Award de Tecnología Innovadora de Display de la International Data Group
More news about: TCL
Jan 19, 2026, 02:00 ET Henlius präsentiert auf der JPM 2026 die Strategie „Globalisation 2.0" sowie einen mittel- bis langfristigen Innovationsfahrplan
Jahr 2026 vor, darunter Serplulimab (Handelsname: Hetronifly® in Europa), ein Anti-PD-1-MAb; HLX22, ein neuartiger Epitop-Anti-HER2-MAb; HLX43, ein PD-L1-ADC; und HLX07, ein Anti-EGFR-MAb.Derzeit umfasst das präklinische Portfolio des Unternehmens mehrere molekulare Modalitäten, darunter Antikörper,
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius presenta su estrategia "Globalización 2.0" y su plan de innovación a medio y largo plazo en JPM 2026
en 2026, incluidos serplulimab (nombre comercial: Hetronifly® en Europa), un mAb anti-PD-1; HLX22, un nuevo mAb anti-HER2 de epítopo; HLX43, un ADC PD-L1; y HLX07, un mAb anti-EGFR.Actualmente, la cartera de activos preclínicos de la Compañía abarca múltiples modalidades moleculares, incluyendo
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius présente sa stratégie « Globalisation 2.0 » et son plan d'innovation à moyen et long terme lors de la conférence JPM 2026
notamment le serplulimab (nom commercial : Hetronifly® en Europe), un AcM anti-PD-1 ; le HLX22, un AcM anti-HER2 à nouvel épitope ; le HLX43, un ADC PD-L1 ; et le HLX07, un AcM anti-EGFR.Actuellement, le portefeuille d'actifs précliniques de la société couvre de multiples modalités moléculaires,
More news about: Henlius
Jan 18, 2026, 19:02 ET Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody
More news about: Harbour BioMed
Jan 17, 2026, 23:09 ET Intelligentes Fahren für Schwerlast-Lkw und unbemannte Logistik
entsprechen, und gleichzeitig chinesische Automobilhersteller bei ihrem Eintritt in den globalen Markt unterstützen, indem es Lösungen der Stufen L2+ bis L3 und L4 anbietet.Auf dem Weg in eine Ära der autonomen Mobilität Mit dem kontinuierlichen Ausbau seiner Geschäftsaktivitäten tritt
More news about: ZYT
Jan 17, 2026, 06:02 ET 大型トラックおよび無人物流分野へインテリジェント・ドライビングを拡大
Passionate）」というエンジニアリング哲学を堅持し、制約のあるハードウェア資源から最高水準の性能を引き出すことに注力しています。大型トラック向けインテリジェント・ドライビング・システムは、ZYT独自の1L3R7Vセンサー構成を採用しており、100TOPSの演算性能を提供するSA8650ドメインコントローラーを搭載しています。その中核には、ZYTが自社開発したエンドツーエンド（End-to-End）モデルを備えています。本システムは大型トラックの利用シーンに最適化されており、0～110 km/hの全速度域にわたって、高速道路ナビゲーション（Navigation on Highway：NOA）、運転支援、
More news about: ZYT
Jan 16, 2026, 18:57 ET Tri-Union Seafoods Identifies Additional Quantities of Recalled Genova® Tuna at Limited Retailers Due to Inadvertent Distribution of Previously Recalled Product
S84N D2L1/21/2028S84N D3L
More news about: Tri-Union Seafoods
Jan 16, 2026, 17:11 ET Where Endurance Meets Lifestyle: Life Time Announces 2026 Athletic Events Calendar
lives through its more than 185 athletic country clubs across the U.S. and Canada, the complimentary and comprehensive Life Time app featuring its L•AI•C™ AI-powered health companion, and more than 30 iconic athletic events. Serving people ages 90 days to 90+ years, the Life Time ecosystem uniquely delivers
More news about: Life Time, Inc.
Jan 16, 2026, 14:31 ET Two Coker, Robb & Cannon Shareholders Earn TBLS Board Certification in Family Law
"Board certification is one of the clearest, most objective markers of specialization in Texas family law," said Attorney & Senior Shareholder Duane L. Coker. "Malorie and Anthony earned a distinction that reflects tested knowledge and sustained experience, and we are proud of them and the fact that
More news about: Coker, Robb & Cannon
Jan 16, 2026, 14:01 ET McCune Law Group to Hold Press Conference on Alleged Civil Rights Violations and Discrimination Against San Bernardino County Employee and his Family on Tuesday, January 20, 2026, at 9:00 AM PST
with the rights afforded to public employees."These cases chronicle a life shattered by avoidable and tragic mistakes," said attorneys Joseph L. Richardson and Brynna D. Popka of McCune Law Group. "San Bernardino County did not search for the truth; they saw a gay man with two adopted sons, looked
More news about: McCune Law Group APC
Jan 16, 2026, 13:35 ET Federal Signal Completes Acquisition of Mega Corp.
2025. "We are excited to complete the acquisition of Mega and formally welcome its talented team to the Federal Signal family," said Jennifer L. Sherman, President and Chief Executive Officer. "Mega represents a compelling strategic fit that enhances our depth in the global metal extraction support
More news about: Federal Signal Corporation
Jan 16, 2026, 11:26 ET Former Miss Universe Canada Delegate Sues Grant Cardone and Cardone Capital, Seeking $500 Million in Florida Defamation Case
https://www.instagram.com/hauteagency?igsh=N255OXhhcGN5NG9l
More news about: TMedia Partners
Jan 16, 2026, 11:10 ET AARP Mississippi Now Accepting 2026 Community Challenge Grant Applications
policymakers to improve the quality of life for people of all ages, especially Mississippians 50 and older," said AARP Mississippi State Director Kimberly L. Campbell, Esq. "We look forward to the opportunity this year to provide increased support to communities across the state." This year, the AARP
More news about: AARP Mississippi
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
drug candidates.Key early-stage assets include:HLX37: PD-L1 × VEGF bispecific antibody developed based on the immune checkpoint inhibitor platform. It demonstrates high PD-L1 binding affinity and achieves higher tumour microenvironment (TME) enrichment vs. combination
More news about: Henlius
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
mFOLFOX6 chemotherapy across wide ranges of PD-L1 and CLDN18.2 expression levels."The dose expansion data reinforce the strong signals we observed in dose escalation. The efficacy is clear at 8 mg/kg, with robust ORRs, including in subgroups defined by low PD-L1 and/or CLDN18.2 expression," said Phillip
More news about: Equity Insider
Jan 16, 2026, 08:00 ET New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
doi:10.1136/gpsych-2021-100724 Pandya M, et al. Where in the Brain Is Depression? Curr Psychiatry Rep. 2012;14:634–642. doi:10.1007/s11920-012-0322-7Zhu L et al. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States. J Manag Care Spec
More news about: Johnson & Johnson
Jan 16, 2026, 07:46 ET The Republic of Ecuador Announces an Offer to Purchase for Cash Certain of its Notes
exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is only directed at and may be communicated to (l) those persons who are existing creditors of the Republic within Article 43(2) of the FSMA (Financial Promotion) Order 2005, as amended, and (2) to any
More news about: The Republic of Ecuador
Jan 16, 2026, 07:30 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
innovation assets in 2026, including serplulimab (trade name: Hetronifly® in Europe), an anti-PD-1 mAb; HLX22, a novel epitope anti-HER2 mAb; HLX43, a PD-L1 ADC; and HLX07, an anti-EGFR mAb.At present, the Company's preclinical asset portfolio spans multiple molecular modalities, including antibodies,
More news about: Henlius
Jan 16, 2026, 06:49 ET Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
here.ReferencesSmith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143.Servais A, et al. Kidney Int. 2012;82(4):454-464.Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015.Data on file using literature
More news about: Swedish Orphan Biovitrum AB